New‐onset pemphigus foliaceus following SARS‐CoV‐2 infection and unmasking multiple sclerosis: A case report

Clinical Case Reports

Parvaneh Hatami¹  Zeinab Aryanian¹  Zeinab Mohseni Afshar²  Arezoo Refaghat³  Nessa Aghazadeh Mohandesi⁴  Fatemeh Mohaghegh⁵  Mohammadjavad Mehdizadeh⁶ 

[1] Autoimmune Bullous Diseases Research Center Tehran University of Medical Sciences Tehran Iran;Clinical Research Development Center Imam Reza Hospital Kermanshah University of Medical Sciences Kermanshah Iran;Department of Dermatology Isfahan University of Medical Sciences Isfahan Iran;Department of Dermatology Mayo Clinic Rochester Minnesota USA;Department of Dermatology Skin Diseases and Leishmaniasis Research Center Isfahan University of Medical Sciences Isfahan Iran;Radiology Department Zahraye Marziyeh Hospital Isfahan Iran;

关键词: COVID‐19;    multiple sclerosis;    pemphigus;    pemphigus foliaceus;    rituximab;    SARS‐Cov‐2;   

DOI  :  10.1002/ccr3.5910

来源: DOAJ

【 摘 要 】

Abstract Development of pemphigus foliaceus (PF) following SARS‐CoV‐2 infection has only been reported in one patient who had received Bamlanivimab and thus might be considered as a drug‐induced case of PF. Here, we reported the first case of PF arising solely after COVID infection without taking any culprit drug.

【 授权许可】

Unknown